奥翔药业
(603229)
| 流通市值：63.85亿 | | | 总市值：63.85亿 |
| 流通股本：8.30亿 | | | 总股本：8.30亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 467,614,591.81 | 308,673,252.77 | 792,759,011.85 | 645,961,585.61 |
| 营业收入 | 467,614,591.81 | 308,673,252.77 | 792,759,011.85 | 645,961,585.61 |
| 二、营业总成本 | 361,464,471.53 | 193,930,900.75 | 670,523,160.48 | 436,884,971.86 |
| 营业成本 | 214,481,231.31 | 116,095,317.31 | 368,562,170.81 | 278,241,914.39 |
| 税金及附加 | 4,262,419.25 | 1,106,399.15 | 10,978,599.06 | 6,959,977.9 |
| 销售费用 | 9,428,774.98 | 3,500,517.94 | 20,246,198.46 | 11,369,986.48 |
| 管理费用 | 44,038,948.33 | 21,663,946.8 | 97,735,857.1 | 62,985,906.17 |
| 研发费用 | 57,873,375.08 | 30,760,235.89 | 167,893,049.2 | 81,618,800.72 |
| 财务费用 | 31,379,722.58 | 20,804,483.66 | 5,107,285.85 | -4,291,613.8 |
| 其中:利息费用 | 5,412,942.3 | 2,825,566.23 | 8,087,550.62 | 5,617,852.04 |
| 其中:利息收入 | 11,877,407.66 | 6,051,232.27 | 23,877,900.15 | 14,708,526.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 26,427,338.21 | -3,035,925.96 | -489,448.22 | 49,477.38 |
| 加:投资收益 | 10,766,110.31 | 3,890,926.75 | 22,281,446.94 | 19,243,464.16 |
| 资产减值损失(新) | -2,186,481.64 | - | -19,583,678.95 | -1,600,811.6 |
| 信用减值损失(新) | -15,137,424.12 | -10,779,372.47 | 4,318,228.36 | -1,959,630.61 |
| 其他收益 | 4,344,281.24 | 2,547,896.84 | 11,282,754.9 | 9,424,226.66 |
| 四、营业利润 | 130,363,944.28 | 107,365,877.18 | 140,045,154.4 | 234,233,339.74 |
| 加:营业外收入 | 600,200 | 600,000 | 271,193.1 | 271,192.69 |
| 减:营业外支出 | 669,541.75 | 635,217.69 | 2,412,490.02 | 1,158,804.36 |
| 五、利润总额 | 130,294,602.53 | 107,330,659.49 | 137,903,857.48 | 233,345,728.07 |
| 减:所得税费用 | 10,453,817.11 | 10,668,162.24 | 7,333,733.88 | 26,313,822.13 |
| 六、净利润 | 119,840,785.42 | 96,662,497.25 | 130,570,123.6 | 207,031,905.94 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 119,840,785.42 | 96,662,497.25 | 130,570,123.6 | 207,031,905.94 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 119,840,785.42 | 96,662,497.25 | 130,570,123.6 | 207,031,905.94 |
| 扣除非经常损益后的净利润 | 80,495,319.25 | 92,378,319.55 | 105,825,488.16 | 183,230,077.39 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.15 | 0.12 | 0.16 | 0.25 |
| (二)稀释每股收益 | 0.15 | 0.12 | 0.16 | 0.25 |
| 八、其他综合收益 | -263,400.55 | 199,836.82 | -262,560.71 | 19,962.48 |
| 归属于母公司股东的其他综合收益 | -263,400.55 | 199,836.82 | -262,560.71 | 19,962.48 |
| 九、综合收益总额 | 119,577,384.87 | 96,862,334.07 | 130,307,562.89 | 207,051,868.42 |
| 归属于母公司股东的综合收益总额 | 119,577,384.87 | 96,862,334.07 | 130,307,562.89 | 207,051,868.42 |
| 公告日期 | 2026-08-29 | 2026-04-29 | 2026-04-29 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |